T2 Biosystms is a diagnostics & research business based in the US. T2 Biosystms shares (TTOO) are listed on the NASDAQ and all prices are listed in US Dollars. T2 Biosystms employs 113 staff and has a trailing 12-month revenue of around $7.2 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $3.09 |
|---|---|
| 52-week range | $2.60 - $46.85 |
| 50-day moving average | $4.60 |
| 200-day moving average | $4.40 |
| Wall St. target price | $5.00 |
| PE ratio | 0.1074 |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $29.70 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $3.09 from 2024-09-05
| 1 week (2024-08-30) | -3.13% |
|---|---|
| 1 month (2024-08-07) | -22.75% |
| 3 months (2024-06-07) | -27.97% |
| 6 months (2024-03-07) | -36.68% |
| 1 year (2023-09-07) | 800.87% |
|---|---|
| 2 years (2022-09-07) | 2,871.15% |
| 3 years (2021-09-07) | 247.97% |
| 5 years (2019-09-06) | 122.30% |
Valuing T2 Biosystms stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of T2 Biosystms's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
T2 Biosystms's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 0x. In other words, T2 Biosystms shares trade at around 0x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
| Revenue TTM | $7.2 million |
|---|---|
| Gross profit TTM | $-24,766,000 |
| Return on assets TTM | -90.46% |
| Return on equity TTM | -622.14% |
| Profit margin | 0% |
| Book value | $-0.34 |
| Market Capitalization | $55.8 million |
TTM: trailing 12 months
We're not expecting T2 Biosystms to pay a dividend over the next 12 months.
T2 Biosystms's shares were split on a 1:100 basis on 12 October 2023. So if you had owned 100 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your T2 Biosystms shares – just the quantity. However, indirectly, the new 9900% higher share price could have impacted the market appetite for T2 Biosystms shares which in turn could have impacted T2 Biosystms's share price.
Over the last 12 months, T2 Biosystms's shares have ranged in value from as little as $2.6 up to $46.85. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while T2 Biosystms's is 0.135. This would suggest that T2 Biosystms's shares are less volatile than average (for this exchange).
T2 Biosystems, Inc. , an in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida panel, a direct-from-blood molecular diagnostic test panel that detects lethal form of common blood stream infections, which cause sepsis and candidemia; T2Bacteria panel, a direct-from-blood molecular diagnostic test panel, which detects bacterial pathogens in blood stream infections; T2Resistance panel, a direct-from-blood test that identifies carbapenem resistance genes; and T2Biothreat, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument and detects biothreat pathogens. In addition, it is developing T2Cauris panel, a direct-from-blood molecular diagnostic test that runs on the T2Dx Instrument and detects Candida auris; and T2Lyme panel, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument to identify the bacteria that cause Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
Use this calculator to quickly see potential outcomes of your options trades.
SoFi, Robinhood, Tastytrade, Webull, Interactive Brokers, E*TRADE, eToro and others top our list for the best options trading platforms.
A covered call is an options trading strategy that allows you to generate income from stocks you already own.
A look at GSD Capital’s highlights, limitations, fees and investment strategies.
Explore the best bonuses for opening a new brokerage account.
Looking for a discount broker like E*TRADE that offers something different? Here are some of the top alternatives to consider.
Charles Schwab and Fidelity are two powerhouse trading platforms for beginner and advanced investors.
Interactive Brokers has advanced charting tools but a high net requirement to qualify.
Discover the top tech stocks poised to lead innovation and offer substantial growth opportunities.
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.